PureTech Health Plcの内部者の所有権
PureTech Health Plcの内部者の所有権は何ですか。
PureTech Health Plcの内部者の所有権は15.21%です。
内部者の所有権の定義は何ですか。
管理の所有権(Insider Ownership)は、発行済株式総数で除したインサイダー（5％超を所有する株主または取締役または役員) が所有する株式総数によって計算されます。
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
LSEのセクタHealth Careにおける内部者の所有権の企業と比べるPureTech Health Plc
PureTech Health Plcは何をしますか。
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
PureTech Health Plcと類似の内部者の所有権
- Paycom Softwareの内部者の所有権は15.18%です。
- Source Servicesの内部者の所有権は15.18%です。
- Paycom Softwareの内部者の所有権は15.18%です。
- APN Industria REITの内部者の所有権は15.19%です。
- Virco Manufacturingの内部者の所有権は15.19%です。
- Cintasの内部者の所有権は15.19%です。
- PureTech Health Plcの内部者の所有権は15.21%です。
- Filae S.Aの内部者の所有権は15.21%です。
- Spectra7 Microsystems Incの内部者の所有権は15.21%です。
- Sound Bancorp Incの内部者の所有権は15.21%です。
- Elixirの内部者の所有権は15.22%です。
- L.S. Starrett Coの内部者の所有権は15.22%です。
- Senmiao Technology Ltdの内部者の所有権は15.23%です。